002424公告！姜伟，被证监会立案！

Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [6][8]. Group 1: Investigation Details - On December 3, Guizhou Bailing announced that Jiang Wei received a notice of investigation from the CSRC due to allegations of insider trading and information disclosure violations [6]. - The investigation is focused on Jiang Wei personally and is stated to have no impact on the company's daily operations or business activities [6]. - Guizhou Bailing has been previously investigated for information disclosure violations, with the CSRC launching an investigation in November 2024, the results of which are still pending [4][8]. Group 2: Company Background and Leadership - Guizhou Bailing was founded in 1999 and specializes in the research, production, and sales of traditional Chinese medicine, with notable products including "Yindan Xinnaotong Soft Capsules" and "Vitamin C Yinqiao Tablets" [10]. - Jiang Wei, born in 1961 and a graduate of Guizhou University of Traditional Chinese Medicine, has been the chairman of Guizhou Bailing since 2007 and led the company to become the first listed company in the traditional Chinese medicine sector in 2010 [7]. Group 3: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported a revenue of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [14]. - As of December 3, the stock price of Guizhou Bailing was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [14]. Group 4: Legal Disputes - Recent legal disputes involving Jiang Wei and Huachuang Securities have drawn significant attention, with Huachuang Securities filing lawsuits against Jiang Wei and others over a total amount of 1.4 billion yuan related to a rescue plan and stock pledge disputes [11]. - Jiang Wei has counter-sued, demanding that Huachuang Securities fulfill its obligations regarding the sale of pledged shares and compensation for losses incurred due to alleged malicious reporting [11].